1. Home
  2. VCEL vs MMS Comparison

VCEL vs MMS Comparison

Compare VCEL & MMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VCEL
  • MMS
  • Stock Information
  • Founded
  • VCEL 1989
  • MMS 1975
  • Country
  • VCEL United States
  • MMS United States
  • Employees
  • VCEL N/A
  • MMS 41100
  • Industry
  • VCEL Biotechnology: Biological Products (No Diagnostic Substances)
  • MMS Business Services
  • Sector
  • VCEL Health Care
  • MMS Consumer Discretionary
  • Exchange
  • VCEL Nasdaq
  • MMS Nasdaq
  • Market Cap
  • VCEL 2.1B
  • MMS 4.0B
  • IPO Year
  • VCEL 1997
  • MMS 1997
  • Fundamental
  • Price
  • VCEL $39.41
  • MMS $71.31
  • Analyst Decision
  • VCEL Strong Buy
  • MMS Buy
  • Analyst Count
  • VCEL 8
  • MMS 1
  • Target Price
  • VCEL $62.00
  • MMS $90.00
  • AVG Volume (30 Days)
  • VCEL 430.8K
  • MMS 396.9K
  • Earning Date
  • VCEL 07-31-2025
  • MMS 08-06-2025
  • Dividend Yield
  • VCEL N/A
  • MMS 1.68%
  • EPS Growth
  • VCEL 521.85
  • MMS 31.21
  • EPS
  • VCEL 0.05
  • MMS 5.00
  • Revenue
  • VCEL $238,541,000.00
  • MMS $5,395,260,000.00
  • Revenue This Year
  • VCEL $23.03
  • MMS $2.13
  • Revenue Next Year
  • VCEL $24.52
  • MMS $3.36
  • P/E Ratio
  • VCEL $765.67
  • MMS $14.28
  • Revenue Growth
  • VCEL 14.80
  • MMS 5.29
  • 52 Week Low
  • VCEL $37.39
  • MMS $63.77
  • 52 Week High
  • VCEL $63.00
  • MMS $93.97
  • Technical
  • Relative Strength Index (RSI)
  • VCEL 38.05
  • MMS 52.23
  • Support Level
  • VCEL $40.53
  • MMS $69.43
  • Resistance Level
  • VCEL $43.57
  • MMS $72.93
  • Average True Range (ATR)
  • VCEL 1.69
  • MMS 1.56
  • MACD
  • VCEL -0.25
  • MMS 0.30
  • Stochastic Oscillator
  • VCEL 0.60
  • MMS 74.12

About VCEL Vericel Corporation

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

About MMS Maximus Inc.

Maximus Inc designs, develops, and delivers programs, enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments; U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.

Share on Social Networks: